Association between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2.

Authors

Kensington Hatcher, Thomas Aaberg, Muna Bitar, David Sarraf

Published in

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Jul 21, 2026. Epub Jul 21, 2026.

Abstract

To evaluate whether oral Age-Related Eye Disease Study (AREDS/2) supplementation is associated with structural or functional disease progression over 24 months in patients with Macular Telangiectasia Type 2 (MacTel).
This post hoc analysis included 208 participants enrolled in two 24-month Phase 3 clinical trials of revakinagene taroretcel-lwey for MacTel (sham, n = 98; treated, n = 110). Consistent AREDS/2 exposure was defined by documented intake at baseline and month 24. The primary outcome was 24-month change in ellipsoid zone (EZ) area loss. Secondary outcomes included changes in reading speed, best-corrected visual acuity (BCVA), and aggregate retinal sensitivity. Non-randomized exposure was adjusted using a doubly robust framework combining inverse probability of treatment weighting (IPTW) and multivariable survey-weighted linear regression.
In the sham cohort, AREDS/2 supplementation was not associated with statistically significant differences in 24-month EZ area loss (P = 0.258). In the treated cohort, an initial association with greater EZ area loss among AREDS/2 users (P = 0.032) became non-significant after full multivariable adjustment for age, sex, and diabetes status (P = 0.577). Secondary functional metrics showed no significant differences between groups across either cohort.
AREDS/2 supplementation was not associated with meaningful differences in structural or functional MacTel progression over a 24-month period. These findings do not provide evidence that routine AREDS/2 supplementation slows EZ area loss or preserves visual function in this population.

PMID:
42479159
Bibliographic data and abstract were imported from PubMed on 21 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.